Courageous Innovation.

A fully integrated, patient-centric biotech company focused on vaccines in support of public health and gene and cell therapies targeting unmet medical needs through Courageous Innovation.

View Corporate Presentation

At Ocugen, we are focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, we are advancing vaccine research in the fight against COVID-19, and our work in cell therapy is aimed at orthopedic disease for which no effective treatment options currently exist.

Scientific Platforms

People all over the world live with desperate health conditions and are waiting for an answer. We can do better. We must do better. That’s why we are pursuing new approaches to medicine—being bold and thinking differently in pursuit of discoveries that could benefit millions of patients.

Watch patient journey video

Vaccines

Ocugen’s mucosal vaccine is a novel adenoviral-vectored COVID-19 vaccine essential for reducing infection and transmission.

Gene Therapies

Ocugen’s modifier gene therapy platform is a new approach to treating inherited retinal diseases, as well as blindness diseases that affects millions.

Cell Therapies

Regenerative cell therapy platform to treat serious conditions like articular cartilage lesions.

Ocugen News

12/19/2024

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

12/11/2024

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

11/27/2024

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

11/20/2024

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

11/19/2024

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

View All

WE ARE OCUGEN

“The promise of helping to transform lives—that’s what drives the work I do at Ocugen. I am proud to be a member of our team of dedicated individuals, collaborating to find solutions to address unmet medical needs, in service for patients.”

— Thais McNeal, Senior Director Government & Industry Affairs, Head Patient Advocacy & Alliance Development

“Healthcare has always been in my DNA and it’s a sector that continues to show us how innovation can change peoples’ lives.”

— Dr. Shankar Musunuri, Chairman, CEO, and co-founder of Ocugen

“We want to offer hope. Not just for vision-related conditions, but for many diseases that seem hopeless.”

— Dr. Arun Upadhyay, Chief Scientific Officer, Head of Research & Development and Medical

“We remind ourselves that nothing is impossible with science; it’s just a matter of figuring things out.”

— Sree Kattala, Research Associate Scientist

Join Our Team

“

INVESTORS

We are developing solutions to medical challenges, approaching healthcare innovation with purpose and agility. We do what it takes to bring more therapeutic options to patients.

Learn More

CORPORATE PRESENTATION

Learn more about our progress and pipeline.

View Now